SEC EDGARSEP 21 min read$ASTH

Kitayama Mitchell W sold (to issuer) $315K of ASTH

Kitayama Mitchell W sold (to issuer) 8,500 shares of Astrana Health, Inc. (ASTH) at $37.09 ($0.32M total) on 2026-08-31.

Original reporting

SEC EDGAR · Kitayama Mitchell W

Published Sep 2, 2026, 12:43 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 2, 2026, 1:23 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ASTH

Neutral

medium confidence

Mentioned

$ASTH

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ASTHNeutralLow

Why it matters

The disclosed sale is the first public report of this transaction, offering fresh data for investors.

Market read

Provides a primary source update on insider ownership, useful for short‑term monitoring.

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: filed after market close on 2026-09-01

Background

Form 4 filings disclose insider transactions; directors' sales are monitored for signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ASTHNeutralMedium confidence

Context

Director Kitayama Mitchell sold 8,500 shares for $315,265, reducing his stake to 24,337 shares.

Expected impact

Minor downward pressure on ASTH price in the short term.

Evidence & confidence

Sale size is small relative to market cap and typical trading volume; impact likely limited.

Market effects

Sector

No significant sector impact; insider sale is company‑specific.

Regional

Limited to investors tracking ASTH.

Global

None

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals and merely portfolio rebalancing.

Key entities

Company
Astrana Health, Inc.
Biopharma company listed on NASDAQ under ticker ASTH.
Individual
Kitayama Mitchell W
Director of Astrana Health who sold shares.

Read at source ← All news

SEP 15

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min

AUG 27

$EVHHighAI 8/10

Unpacking Q2 Earnings: Hims & Hers Health (NYSE:HIMS) In The Context Of Other Healthcare Technology Stocks

Evolent Health (EVH) reported Q2 revenue of $652.5M, up 46.9% YoY, beating estimates. Astrana Health (ASTH) reported $972.5M, up 48.5%, missing estimates. Tandem Diabetes (TNDM) reported $254.6M, up 5.8%, in line with estimates. GoodRx (GDRX) reported $200.4M, down 1.3%, beating estimates. All stocks rose post-earnings.

yahoo.com3 min

AUG 13

$ASTHMedAI 8/10

Astrana Health (ASTH) Q2 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.

fool.com7 min

AUG 7

$ASTHMedAI 8/10

Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised

Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.

yahoo.com4 min

AUG 6

$ASTHMed

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non

Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.

financialcontent.com6 min